machmit schreef op 25 november 2015 14:44:
P.M. ter bemoediging:
Other products in the sales portfolio also saw strong growth with Uceris up 20%, Relistor scripts up 36% and Apriso up 7% year over year. Ruconest was up 29% on a sequential basis from last quarter.
We expect revenues attributable to Salix will be approximately $600 million in the fourth quarter, and approximately $1.35 billion for 2015. We continue to take a conservative approach to our sales expectations until this business is completely normalized.
And then with Salix, another set of products they are quite durable and with a lot of organic growth. So we've been debating but I think given, again, everything that's happening, everything that's happened, what's happened to our multiple, I think that there's a reasonable chance that something happens over the next 12 months or so.